Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 3 4Phase NA 2Phase 1/2 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Unknown 6Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

HER2-expressing Advanced Solid Tumors 1Breast Cancer Metastatic 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × pyrotinib × Clear all
NCT06718933 2025-02-06

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

Fudan University

Phase 1/2 Recruiting
74 enrolled
Breast

Breast Cancer Metastatic

NCT06015048 2024-08-05

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Recruiting
364 enrolled
Other solid neoplasm

HER2-expressing Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡